Effectiveness of Gene Editing in Human Stem Cells Improves Tenfold Using New Technique
For the first time, researchers have employed a gene-editing technique involving low-dose irradiation to edit the genome of patient stem cells, according to a study published in the journal Stem Cells Translational Medicine. This method, developed by researchers in the Cedars-Sinai Board of Governors Regenerative Medicine Institute, is 10 times more effective than techniques currently in use.
“This novel technique allows for far more efficient gene editing of stem cells and will increase the speed of new discoveries in the field,” said co-senior author Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute.
The irradiation method could prove effective in learning more about diseases such as spinal muscular atrophy, muscular dystrophy and Huntington’s disease. Gene editing allows scientists to correct disease causing mutations and, theoretically, cure the disease in the petri dish. Additionally, gene-editing technology allows scientists to create disease mutations in normal cells, thus modeling human disease.
When using this form of gene editing, Cedars-Sinai scientists can more efficiently insert reporter genes that glow when a stem cell turns into a specific cell of the body. For example, stem cells would turn green when converted into a heart cell and red when turned into a neuron.
“The combination of low-dose irradiation and correct gene copy will accelerate our ability to model human disease using stem cells from patients with many different disorders,” said co-senior author Vaithilingaraja Arumugaswami, MVSc, PhD, director of the Pancreas and Liver Program in the Cedars-Sinai Board of Governors Regenerative Medicine Institute.
Over the past few years, the field of creating human diseases in the dish using stem cells has expanded rapidly. This work allows scientists to test novel drugs on human cells that carry disease-causing genes.
“Radiation, which is normally considered harmful, has proven beneficial in gene editing,” said Svendsen. This new technique will help us establish far more accurate models and accelerate the discovery process.”.
Read more: Using Low-Dose Irradiation, Researchers Can Now Edit Human Genes
The Latest on: Gene Editing
[google_news title=”” keyword=”Gene Editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene Editing
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Healthon May 3, 2024 at 7:07 am
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy ...
- Moderna ends gene editing alliance with Metagenomion May 2, 2024 at 9:27 am
Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.
- Moderna Walks Away from Potential $3B Gene Editing Deal with Metagenomion May 2, 2024 at 4:37 am
Citing a strategic prioritization by Moderna, Metagenomi announced Wednesday that the partners have “mutually agreed” to terminate their gene editing agreement.
- 3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaireon May 2, 2024 at 3:04 am
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023. With it, we can remove cells from the body ...
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systemson May 1, 2024 at 3:00 pm
This announcement represents a renewed opportunity to advance curative genetic medicine through the translation of Metagenomi’s broad toolbox of wholly-owned gene editing technologies, as well as a ...
- Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chiefon May 1, 2024 at 1:03 pm
Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it's backing out.
- Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlighton May 1, 2024 at 1:00 pm
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks.
- Invest In A Revolutionary Gene Therapy With CRISPR Therapeuticson April 30, 2024 at 10:25 am
CRISPR Therapeutics' Casgevy could generate significant shareholder value if proven to be successful. Learn why I am highly bullish on CRSP stock.
- Boosting crop colors with gene editing can improve weed controlon April 30, 2024 at 1:53 am
At the heart of this progressive strategy lies the concept of modifying the composition of crops with gene editing ...
- Gene seekers discover atypical genes that control multiple valuable soybean traitson April 30, 2024 at 1:27 am
A team led by Purdue University soybean geneticist Jianxin Ma has developed a new biotechnological tool for the domestication of desirable traits from wild soybeans, such as resistance to leafhopper ...
via Bing News